PE20200700A1 - Compuestos macrociclicos y usos de los mismos - Google Patents

Compuestos macrociclicos y usos de los mismos

Info

Publication number
PE20200700A1
PE20200700A1 PE2020000127A PE2020000127A PE20200700A1 PE 20200700 A1 PE20200700 A1 PE 20200700A1 PE 2020000127 A PE2020000127 A PE 2020000127A PE 2020000127 A PE2020000127 A PE 2020000127A PE 20200700 A1 PE20200700 A1 PE 20200700A1
Authority
PE
Peru
Prior art keywords
independently
compound
deuterium
fluoro
chloro
Prior art date
Application number
PE2020000127A
Other languages
English (en)
Spanish (es)
Inventor
Jingrong Jean Cui
Evan W Rogers
Jane Ung
Jeffrey Whitten
Dayong Zhai
Wei Deng
Xin Zhang
Zhongdong Huang
Jing Liu
Han Zhang
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65039935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200700(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of PE20200700A1 publication Critical patent/PE20200700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2020000127A 2017-07-28 2018-07-26 Compuestos macrociclicos y usos de los mismos PE20200700A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538193P 2017-07-28 2017-07-28
US201862700990P 2018-07-20 2018-07-20
PCT/US2018/043817 WO2019023417A1 (en) 2017-07-28 2018-07-26 MACROCYCLIC COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
PE20200700A1 true PE20200700A1 (es) 2020-06-23

Family

ID=65039935

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000127A PE20200700A1 (es) 2017-07-28 2018-07-26 Compuestos macrociclicos y usos de los mismos

Country Status (29)

Country Link
US (4) US11286264B2 (enExample)
EP (1) EP3658148B1 (enExample)
JP (2) JP7224334B2 (enExample)
KR (1) KR102645316B1 (enExample)
CN (1) CN111182903A (enExample)
AU (1) AU2018306328B2 (enExample)
BR (1) BR112020001695A2 (enExample)
CA (1) CA3069232A1 (enExample)
CL (1) CL2020000169A1 (enExample)
CO (1) CO2020000633A2 (enExample)
DK (1) DK3658148T3 (enExample)
ES (1) ES2986593T3 (enExample)
FI (1) FI3658148T3 (enExample)
HR (1) HRP20241197T1 (enExample)
IL (1) IL271964B2 (enExample)
LT (1) LT3658148T (enExample)
MY (1) MY201925A (enExample)
PE (1) PE20200700A1 (enExample)
PH (1) PH12020500033A1 (enExample)
PL (1) PL3658148T3 (enExample)
PT (1) PT3658148T (enExample)
RS (1) RS65884B1 (enExample)
SA (1) SA520411108B1 (enExample)
SG (1) SG11202000356VA (enExample)
SI (1) SI3658148T1 (enExample)
SM (1) SMT202400343T1 (enExample)
TW (1) TWI818917B (enExample)
UA (1) UA126158C2 (enExample)
WO (1) WO2019023417A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
WO2017015367A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
US20220177486A1 (en) * 2019-03-11 2022-06-09 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
WO2021063276A1 (zh) * 2019-09-30 2021-04-08 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
US20250262216A1 (en) * 2020-03-02 2025-08-21 Turning Point Therapeutics, Inc. Therapeutic uses of macrocyclic compounds
WO2021244609A1 (zh) * 2020-06-04 2021-12-09 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
IL301385A (en) 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
CN114685532B (zh) * 2020-12-31 2026-06-16 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
WO2022246092A1 (en) * 2021-05-21 2022-11-24 Blossomhill Therapeutics, Inc. Macrocyclic compounds for treating disease
CN116063326B (zh) * 2021-11-02 2025-08-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
EP4433462A4 (en) * 2021-11-16 2025-07-16 Prodeg Llc USP9X INHIBITORS
US12168640B2 (en) 2021-11-16 2024-12-17 ProDeg, LLC USP9X inhibitors
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149869T3 (es) 1993-03-25 2000-11-16 Upjohn Co Derivados de indol sustituidos por formil o ciano con actividad dopominergica.
KR100340159B1 (ko) 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ATE328888T1 (de) 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
RU2275373C2 (ru) 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
ES2668834T3 (es) 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
BRPI0914404A2 (pt) 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
CA2772974C (en) 2011-06-10 2016-04-05 Maintech Co., Ltd. Anti-soiling agent composition for dry part of paper-making process
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
MX2014001945A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Procedimiento e intermedios para la preparacion de macrolactamas.
MX347765B (es) 2011-09-30 2017-05-12 Oncodesign Sa Inhibidores macrociclicos de la quinasa flt3.
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
TWI688567B (zh) * 2014-09-11 2020-03-21 美商特普醫葯公司 作為蛋白質激酶之調節劑的二芳基巨環
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
RS63359B1 (sr) * 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
AU2017348826B2 (en) * 2016-10-28 2021-12-02 Centaurus Biopharma Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
US11584759B2 (en) 2018-04-18 2023-02-21 Hitgen Inc. Macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
LT3658148T (lt) 2024-09-10
CL2020000169A1 (es) 2020-08-14
US20210214373A1 (en) 2021-07-15
RS65884B1 (sr) 2024-09-30
IL271964B1 (en) 2024-08-01
BR112020001695A2 (pt) 2020-07-21
JP7554300B2 (ja) 2024-09-19
ES2986593T3 (es) 2024-11-12
WO2019023417A1 (en) 2019-01-31
PH12020500033A1 (en) 2020-09-28
US20240391935A1 (en) 2024-11-28
EP3658148A4 (en) 2021-04-28
TW201920198A (zh) 2019-06-01
US20220324879A1 (en) 2022-10-13
AU2018306328A1 (en) 2020-01-16
MY201925A (en) 2024-03-23
JP7224334B2 (ja) 2023-02-17
JP2023065403A (ja) 2023-05-12
KR102645316B1 (ko) 2024-03-07
PL3658148T3 (pl) 2024-10-07
US12606571B2 (en) 2026-04-21
JP2020528907A (ja) 2020-10-01
HRP20241197T1 (hr) 2024-11-22
KR20200034998A (ko) 2020-04-01
AU2018306328B2 (en) 2023-03-09
SMT202400343T1 (it) 2024-11-15
EP3658148A1 (en) 2020-06-03
US11155563B2 (en) 2021-10-26
EP3658148B1 (en) 2024-07-10
CO2020000633A2 (es) 2020-01-31
TWI818917B (zh) 2023-10-21
PT3658148T (pt) 2024-08-26
US11981684B2 (en) 2024-05-14
US20200157119A1 (en) 2020-05-21
FI3658148T3 (fi) 2024-09-20
SG11202000356VA (en) 2020-02-27
IL271964A (en) 2020-02-27
IL271964B2 (en) 2024-12-01
DK3658148T3 (da) 2024-10-07
UA126158C2 (uk) 2022-08-25
SI3658148T1 (sl) 2024-10-30
US11286264B2 (en) 2022-03-29
CA3069232A1 (en) 2019-01-31
SA520411108B1 (ar) 2024-03-03
CN111182903A (zh) 2020-05-19

Similar Documents

Publication Publication Date Title
PE20181491A1 (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20180742A1 (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20200937A1 (es) Compuestos macrociclicos para tratar enfermedades
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
PE20180949A1 (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2016002348A1 (es) Agonistas del receptor muscarínico
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
PE20240775A1 (es) Compuestos antivirales
CL2022001710A1 (es) Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
MX2020011469A (es) Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos.
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR109315A1 (es) Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
PE20200292A1 (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20200340A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR104174A1 (es) Oxadiazoles sustituidos con deuterio